As mechanisms of immunogenicity in anti-VEGF drugs are still not perfectly understood (possibly due to anti-drug antibodies, protein source, molecular drug structure, drug impurities, injection material impurities, procedure-related factors, patient factors, and/or others), and might be different for different types for IOI (acute inflammation/sterile endophthalmitis versus delayed onset inflammation/vasculitis), further RWD with longer follow-up should shed more light on the mechanisms and incidence of IOIs due to anti-VEGF drugs [6,7]. Here, VEGFA is linked to vasculitis.